Helen M. Thackray - Dec 15, 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: Chief R&D Officer
Signature: /s/ Alane P. Barnes, by power of attorney
Stock symbol: BCRX
Transactions as of: Dec 15, 2022
Transactions value $: -$34,031
Form type: 4
Date filed: 12/19/2022, 03:58 PM
Previous filing: Jun 17, 2022
Next filing: Dec 21, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Sale	-$34K	-3.13K	-2.29%	$10.89	133K	Dec 15, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 11,000 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2	The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.33. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Content

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 11,000 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.50 to $11.33. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.